ARWR Arrowhead Pharmaceuticals Inc

$37.50

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 10/6/2025

About Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops drugs for the treatment of intractable diseases in the United States. The company is headquartered in Pasadena, California.

Website: https://arrowheadpharma.com

Sector
TRADE & SERVICES
Industry
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
September
CIK
879407
Address
225 SOUTH LAKE AVENUE, SUITE 1050, PASADENA, CA, US
Valuation
Market Cap
$1.54B
P/E Ratio
nan
PEG Ratio
-1.32
Price to Book
29.35
Performance
EPS
$-5.15
Dividend Yield
—
Profit Margin
0.00%
ROE
-565.00%
Technicals
50D MA
$15.79
200D MA
$20.48
52W High
$30.41
52W Low
$9.57
Fundamentals
Shares Outstanding
137M
Target Price
$45.64
Beta
1.00

ARWR EPS Estimates vs Actual

● Estimated
● Actual

ARWR News & Sentiment

Sep 29, 2025 • Benzinga BULLISH
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals - Arrowhead Pharma ( NASDAQ:ARWR ) , Assembly Biosciences ( NASDAQ:ASMB )
Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action.
Sep 10, 2025 • Zacks Commentary SOMEWHAT-BULLISH
NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline
Novartis is set to acquire Tourmaline Bio for $1.4B, adding late-stage anti-IL-6 candidate pacibekitug to its cardiovascular pipeline.
Sep 05, 2025 • Motley Fool NEUTRAL
Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal
The announcement of a landmark deal with a pharmaceutical giant validates Arrowhead's technology.
Sep 03, 2025 • Zacks Commentary SOMEWHAT-BULLISH
NVS Inks a Licensing Deal With Arrowhead for siRNA Therapy
Novartis strikes a $200M licensing deal with Arrowhead for ARO-SNCA, aiming to advance treatments for Parkinson???s Disease.
Sep 02, 2025 • Benzinga SOMEWHAT-BULLISH
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday - Apollo Asset Management ( NYSE:APO ) , Air Lease ( NYSE:AL )
U.S. stocks were lower, with the Dow Jones index falling over 250 points on Tuesday. Shares of Air Lease Corporation AL rose sharply during Tuesday's session after the aircraft lessor said it will be acquired by a newly formed Dublin-based holding company backed by Sumitomo Corp.
Aug 14, 2025 • Zacks Commentary NEUTRAL
Sarepta Sells Arrowhead Stake to Fund Milestone Payment
Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.
Sentiment Snapshot

Average Sentiment Score:

0.121
50 articles with scored sentiment

Overall Sentiment:

Neutral

ARWR Reported Earnings

Feb 04, 2025
Dec 31, 2024 (Pre market)
-0.67 Surprise
  • Reported EPS: $-1.39
  • Estimate: $-0.72
  • Whisper: —
  • Surprise %: -92.2%
Nov 27, 2024
Sep 30, 2024 (Pre market)
-0.45 Surprise
  • Reported EPS: $-1.37
  • Estimate: $-0.92
  • Whisper: —
  • Surprise %: -48.6%
Aug 08, 2024
Jun 30, 2024 (Post market)
-0.83 Surprise
  • Reported EPS: $-1.38
  • Estimate: $-0.55
  • Whisper: —
  • Surprise %: -150.9%
May 09, 2024
Mar 31, 2024 (Post market)
-0.86 Surprise
  • Reported EPS: $-1.02
  • Estimate: $-0.16
  • Whisper: —
  • Surprise %: -537.5%
Feb 06, 2024
Dec 31, 2023 (Post market)
-0.42 Surprise
  • Reported EPS: $-1.24
  • Estimate: $-0.82
  • Whisper: —
  • Surprise %: -51.2%
Nov 29, 2023
Sep 30, 2023 (Post market)
-0.42 Surprise
  • Reported EPS: $-1.02
  • Estimate: $-0.60
  • Whisper: —
  • Surprise %: -70.0%
Aug 07, 2023
Jun 30, 2023 (Post market)
-0.31 Surprise
  • Reported EPS: $-0.96
  • Estimate: $-0.65
  • Whisper: —
  • Surprise %: -47.7%
May 02, 2023
Mar 31, 2023 (Post market)
1.09 Surprise
  • Reported EPS: $0.45
  • Estimate: $-0.64
  • Whisper: —
  • Surprise %: 170.3%
Feb 06, 2023
Dec 31, 2022 (Post market)
-0.83 Surprise
  • Reported EPS: $-0.39
  • Estimate: $0.44
  • Whisper: —
  • Surprise %: -188.6%

Financials